Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study-Reference-Cited by-同舟云学术

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Published:2024-08-12 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Graff Julie N.,Hoimes Christopher J.,Gerritsen Winald R.,Vaishampayan Ulka N.,Elliott Tony,Hwang Clara^ORCID,ten Tije Albert J.,Omlin Aurelius,McDermott Raymond S.,Fradet Yves,Tagawa Scott T.^ORCID,Kilari Deepak,Ferrario Cristiano,Uemura Hiroji,Jones Robert J.^ORCID,Fukasawa Satoshi,Peer Avivit,Niu Cuizhen,Poehlein Christian H.,Qiu Ping,Suttner Leah,de Wit Ronald^ORCID,Schloss Charles,de Bono Johann S.^ORCID,Antonarakis Emmanuel S.^ORCID

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41391-024-00865-5.pdf

Reference13 articles.

1. European Association of Urology. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer 2022. European Association of Urology: Arnhem, Netherlands; 2022. Available from: https://uroweb.org/guidelines/prostate-cancer.

2. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline part II. J Urol. 2021;205:22–9.

3. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46.

4. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86.

5. Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395–405.